193 related articles for article (PubMed ID: 23079960)
1. Osteopontin promoter polymorphisms at locus -443 significantly affect the metastasis and prognosis of human hepatocellular carcinoma.
Dong QZ; Zhang XF; Zhao Y; Jia HL; Zhou HJ; Dai C; Sun HJ; Qin Y; Zhang WD; Ren N; Ye QH; Qin LX
Hepatology; 2013 Mar; 57(3):1024-34. PubMed ID: 23079960
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma.
Pan HW; Ou YH; Peng SY; Liu SH; Lai PL; Lee PH; Sheu JC; Chen CL; Hsu HC
Cancer; 2003 Jul; 98(1):119-27. PubMed ID: 12833464
[TBL] [Abstract][Full Text] [Related]
3. Correlation and prognostic value of osteopontin and Bcl-2 in hepatocellular carcinoma patients after curative resection.
Deng B; Zhang XF; Zhu XC; Huang H; Jia HL; Ye QH; Dong QZ; Qin LX
Oncol Rep; 2013 Dec; 30(6):2795-803. PubMed ID: 24065086
[TBL] [Abstract][Full Text] [Related]
4. Thrombin is a therapeutic target for metastatic osteopontin-positive hepatocellular carcinoma.
Xue YH; Zhang XF; Dong QZ; Sun J; Dai C; Zhou HJ; Ren N; Jia HL; Ye QH; Qin LX
Hepatology; 2010 Dec; 52(6):2012-22. PubMed ID: 20890897
[TBL] [Abstract][Full Text] [Related]
5. Combination of osteopontin with peritumoral infiltrating macrophages is associated with poor prognosis of early-stage hepatocellular carcinoma after curative resection.
Zhu W; Guo L; Zhang B; Lou L; Lin Z; Zhu X; Ren N; Dong Q; Ye Q; Qin L
Ann Surg Oncol; 2014 Apr; 21(4):1304-13. PubMed ID: 24366422
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma.
Xie H; Song J; Du R; Liu K; Wang J; Tang H; Bai F; Liang J; Lin T; Liu J; Fan D
Dig Liver Dis; 2007 Feb; 39(2):167-72. PubMed ID: 17161983
[TBL] [Abstract][Full Text] [Related]
7. Aberrant expressions of annexin A10 short isoform, osteopontin and alpha-fetoprotein at chromosome 4q cooperatively contribute to progression and poor prognosis of hepatocellular carcinoma.
Peng SY; Ou YH; Chen WJ; Li HY; Liu SH; Pan HW; Lai PL; Jeng YM; Chen DC; Hsu HC
Int J Oncol; 2005 Apr; 26(4):1053-61. PubMed ID: 15754002
[TBL] [Abstract][Full Text] [Related]
8. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin.
Yu MC; Lee YS; Lin SE; Wu HY; Chen TC; Lee WC; Chen MF; Tsai CN
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S455-63. PubMed ID: 21822558
[TBL] [Abstract][Full Text] [Related]
9. Thirty-kilodalton Tat-interacting protein suppresses tumor metastasis by inhibition of osteopontin transcription in human hepatocellular carcinoma.
Zhao J; Lu B; Xu H; Tong X; Wu G; Zhang X; Liang A; Cong W; Dai J; Wang H; Wu M; Guo Y
Hepatology; 2008 Jul; 48(1):265-75. PubMed ID: 18537194
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and Prognostic Roles of Serum Osteopontin and Osteopontin Promoter Polymorphisms in Hepatitis B-related Hepatocellular Carcinoma.
Chimparlee N; Chuaypen N; Khlaiphuengsin A; Pinjaroen N; Payungporn S; Poovorawan Y; Tangkijvanich P
Asian Pac J Cancer Prev; 2015; 16(16):7211-7. PubMed ID: 26514514
[TBL] [Abstract][Full Text] [Related]
11. Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria.
Sieghart W; Wang X; Schmid K; Pinter M; König F; Bodingbauer M; Wrba F; Rasoul-Rockenschaub S; Peck-Radosavljevic M
J Hepatol; 2011 Jan; 54(1):89-97. PubMed ID: 20970216
[TBL] [Abstract][Full Text] [Related]
12. The implication of osteopontin (OPN) expression and genetic polymorphisms of OPN promoter in oral carcinogenesis.
Chiu YW; Tu HF; Wang IK; Wu CH; Chang KW; Liu TY; Kao SY
Oral Oncol; 2010 Apr; 46(4):302-6. PubMed ID: 20219412
[TBL] [Abstract][Full Text] [Related]
13. Osteopontin, a single marker for predicting the prognosis of patients with tumor-node-metastasis stage I hepatocellular carcinoma after surgical resection.
Chen RX; Xia YH; Cui JF; Xue TC; Ye SL
J Gastroenterol Hepatol; 2010 Aug; 25(8):1435-42. PubMed ID: 20659235
[TBL] [Abstract][Full Text] [Related]
14. [Interference of osteopontin expression inhibits the invasion and metastasis of human hepatocellular carcinoma cell lines].
Lin F; Li YY; Xia JT; Wen MJ; Lai YY; Cai WS; Wu ZF; Fan SF
Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):422-5. PubMed ID: 19567019
[TBL] [Abstract][Full Text] [Related]
15. Effects of E-cadherin (CDH1) gene promoter polymorphisms on the risk and clinicopathological development of hepatocellular carcinoma.
Chien MH; Yeh KT; Li YC; Hsieh YH; Lin CH; Weng MS; Kuo WH; Yang SF
J Surg Oncol; 2011 Sep; 104(3):299-304. PubMed ID: 21462191
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via a mechanism involving MMP-2 and uPA.
Chen RX; Xia YH; Xue TC; Zhang H; Ye SL
Oncol Rep; 2011 Mar; 25(3):803-8. PubMed ID: 21174062
[TBL] [Abstract][Full Text] [Related]
17. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma.
Yuan RH; Jeng YM; Chen HL; Lai PL; Pan HW; Hsieh FJ; Lin CY; Lee PH; Hsu HC
J Pathol; 2006 Aug; 209(4):549-58. PubMed ID: 16739096
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin promotes epithelial-mesenchymal transition of hepatocellular carcinoma through regulating vimentin.
Dong Q; Zhu X; Dai C; Zhang X; Gao X; Wei J; Sheng Y; Zheng Y; Yu J; Xie L; Qin Y; Qiao P; Zhou C; Yu X; Jia H; Ren N; Zhou H; Ye Q; Qin L
Oncotarget; 2016 Mar; 7(11):12997-3012. PubMed ID: 26824421
[TBL] [Abstract][Full Text] [Related]
19. [Osteopontin as a potential biomarker of metastasis and recurrence for hepatocellular carcinoma].
Cui BK; Zhang CQ; Zhang Y; Yuan YF; Zhang YQ; Shi M; Chen MS; Li SP; Li JQ
Ai Zheng; 2006 Jul; 25(7):876-9. PubMed ID: 16831281
[TBL] [Abstract][Full Text] [Related]
20. Association of specific genotypes in metastatic suppressor HTPAP with tumor metastasis and clinical prognosis in hepatocellular carcinoma.
Ren N; Wu JC; Dong QZ; Sun HJ; Jia HL; Li GC; Sun BS; Dai C; Shi J; Wei JW; Sheng YY; Zhou HJ; Ye QH; Qin LX
Cancer Res; 2011 May; 71(9):3278-86. PubMed ID: 21531764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
